revive-therapeutics.png
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
September 18, 2024 07:00 ET | Revive Therapeutics Ltd.
TORONTO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Logo_final_color.png
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
September 16, 2024 06:30 ET | Cybrexa Therapeutics
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
MetasTx-Logo_HoRes.jpg
Harvey Homan to Highlight MetasTx’s Game-Changing Approach to Cancer Treatment at PA Life Science Futures
September 12, 2024 06:58 ET | MetasTx LLC
MetasTx aims to revolutionize cancer treatment by targeting p21-activated kinase (PAK-1), a critical driver of metastasis in solid tumors.
factMR-logo.png
Gamification Mobile Application in Healthcare Market is Expected to Hit US$ 31,168.1 Million by 2034 | Fact.MR Report
September 12, 2024 06:00 ET | FACT.MR
Rockville, MD, Sept. 12, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global gamification mobile application in healthcare market is...
Radiance BioPharma sponsoring Investor Cruise Event 2024
August 29, 2024 15:30 ET | Radiance BioPharma
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Radiance Biopharma Inc., a biopharmaceutical company developing next generation Antibody Drug Conjugates and Bispecific Antibody Drug Conjugates announced...
revive-therapeutics.png
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
August 28, 2024 07:00 ET | Revive Therapeutics Ltd.
TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Federal report illum
Federal report illuminates need for disability inclusion in clinical trials
August 14, 2024 12:18 ET | National Council on Disability
WASHINGTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Today, the National Council on Disability (NCD) released a timely report on exclusionary practices that prevent people with disabilities from...
revive-therapeutics.png
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
July 02, 2024 13:58 ET | Revive Therapeutics Ltd.
TORONTO, July 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...